MAIA Biotechnology, Inc.’s Post

Revolutionizing Oligonucleotide Therapeutics: pacDNA Inc. Presents at Venturium’24! The future of medicine is here! Join the Northeastern University Center for Research Innovation (CRI) at Venturium’24, a virtual pitch event showcasing groundbreaking academic spinouts on May 22nd. We're thrilled to introduce pacDNA, a company on a mission to transform oligonucleotide therapeutics. Their innovative Brushield™ technology unlocks the potential for life-changing treatments. Here's why pacDNA is a game-changer in drug development:  ✔ Unlocking New Therapeutic Frontiers: Brushield™ enables oligonucleotide drugs to reach previously inaccessible organs and tissues, opening doors for treatments in areas like cancer, immunology, and more.  ✔ Enhanced Potency & Safety: This revolutionary technology delivers more potent drugs with reduced side effects, offering significant advantages over traditional therapies.  ✔ Faster Drug Development: pacDNA's platform accelerates the journey from promising candidate to Investigational New Drug (IND) stage, speeding up the path to effective treatments. Join us at Venturium‘24 on May 22nd to learn more.  Venturium'24 is an exclusive event is for VCs, venture studios, accelerators, incubators, industry partners, and entrepreneurs. Request your invitation by contacting criventures@northeastern.edu. Ke Zhang Northeastern University PCI Ventures Innovate Carolina Kentucky Commercialization Ventures Rutgers Research Katie Hemphill Salil Darji #Venturium2024 #NortheasternUniversity #drugdevelopment

Bolt Biotherapeutics is halting its lead cancer drug BDC-1001, laying off 50% of staff, and shifting focus to early-stage candidates BDC-3042 (Phase 1) and BDC-4182 (preclinical). Key Insights - ▪️ New Direction: Prioritizing innovative ISAC technology for anti-tumor responses. ▪️ Partnerships: Continued ISAC research supported by Genmab and Toray. ▪️ Leadership Change: Willie Quinn steps in as CEO. ▪️ Impact: Changes aim to extend cash runway into 2026; stock dropped 34%. Questions - ▪️ How will this strategic shift impact Bolt’s future? ▪️ Can ISAC technology succeed despite high risks? ▪️ What does this mean for cancer drug innovation? #Biotech #CancerResearch #ISAC #BoltBiotherapeutics

At the dawn of 2024, there’s a sense of renewed optimism in the biotech sector despite recent sector-specific challenges. This week, the J.P. Morgan Health Care Conference witnessed strong deal-making activity. Here's how #Biotech bounces back at JPM 2024: https://lnkd.in/eNsKYR7N #ObesityDrugs #AntibodyDrugs #funding #RandD #ClinicalDevelopment #biotechnology #oncology

🚀 One-shot design of a differentiated BRD9 inhibitor using the QuanMol ReDefine platform Bromodomain-containing protein 9 (BRD9), a promising therapeutic target in cancer treatment, has been the focus of many discovery programs, including published works by Boehringer Ingelheim, GSK, AstraZeneca, and Genentech, among others. Due to its compact protein structure, developing novel inhibitors for BRD9 with a high potency poses significant challenges. QuanMol’s one-shot de novo design of a novel BRD9 inhibitor sets a new standard of in silico discovery with: ■ 60 nM Potency: Validated by SPR, this represents a significant advancement over the usual micromolar activity found in virtual screenings and is even more potent than some advanced compounds. ■ Unique Scaffold & Binding Mode: Our approach introduces a novel chemical structure with differentiated binding interactions. ■ Highly Efficient Precision Design: Created precisely in just one attempt and within two hours, demonstrating our platform's capability to significantly accelerate drug discovery. At QuanMol, we aim to narrow the translational gap in small-molecule therapeutics across the industry, enhancing your R&D efficiency with our discovery solutions. This achievement with BRD9 is a testament to our mission and the capability of the AI-powered QuanMol ReDefine platform. Interested in a partnership? Let's connect at connect@quanmol.com. #biotech #pharma #ai #drugdiscovery #drugdesign #biology #quanmol #quanmoltech

☢️ 𝐓𝐡𝐞 𝐫𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐫𝐞𝐧𝐚𝐢𝐬𝐬𝐚𝐧𝐜𝐞 The commercial success of second-generation radiopharmaceuticals in oncology has resulted in a surge of deals and increased venture financing. The last 5 years have seen 86 strategic deals, including 26 collaboration/co-development and 26 licensing-based agreements. The sector is experiencing a surge in financing, particularly for cancer indications. Since 2018, financing activity has been steadily increasing, with a dominance in Series A (56%) and B (32%) funding rounds. In the first three quarters of 2023 alone, the average financing has doubled compared to the entire year of 2018, signalling robust interest and investment in the development and clinical progression of these innovative therapies, with a special focus on the theranostic area. The radiopharmaceutical space is poised for growth, expanding into other fields such as neurology and bringing new companies and VCs to the table. 𝘞𝘩𝘢𝘵 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯𝘴 𝘥𝘰 𝘺𝘰𝘶 𝘦𝘹𝘱𝘦𝘤𝘵 𝘵𝘰 𝘴𝘦𝘦 𝘯𝘦𝘹𝘵 𝘪𝘯 𝘳𝘢𝘥𝘪𝘰𝘱𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭𝘴? Credits: Back Bay Life Science Advisors Brianne Sullivan, PhD Andrew Davis Peter Bak   More info: https://lnkd.in/dn7M6VZN #biotech #pharma #drugdevelopment #womeninbusiness #drjojo

Recognizing the pervasive and systemic reality of multibillion-dollar losses from late-stage clinical trial failures, Predictive Oncology recently announced the expansion of its live-cell tumor platform to de-risk drug discovery and accelerate pipeline development. The company — leveraging its artificial intelligence and machine learning capabilities —  is now mining its extensive biobank of cryogenically preserved patient-derived live-cell tumor samples, across 137 different tumor types to account for patient heterogeneity ahead of any clinical phase development work. The ability to accelerate drug development timelines would allow pharmaceutical companies to make critical go/no go decisions, redirect resources or reprioritize R&D efforts more quickly and efficiently. To learn more about how Predictive Oncology has successfully demonstrated its ability to increase the Probability of Technical Success (PTS) by incorporating real-world applications, please visit https://lnkd.in/gvnTrtJ5. For investors, click here https://lnkd.in/gb9BepZA. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech #lifesciences

Join us for our Healthcare Virtual Summit Starting Tuesday, October 15th, 9:00 AM ET This event is intended for Institutions and members of M-Vest only. To attend, sign up to become an M-Vest member: https://lnkd.in/e_5buqAg Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. We also plan to host several topical industry panels that promise to be timely and engaging. Precision and Immune Oncology Panel: Synthetic Lethality and BiSpecifics continue to emerge and chase the high-value ADCs; Can a bacterial protein emerge as the ideal combo with a PD1; Tumor microenvironment in focus…lots to talk about as these spaces continue to advance and capture investor attention. Jason McCarthy, Ph.D., Chad Yahn, Aprea Therapeutics, Context Therapeutics, TuHURA Biosciences, Inc.

Paul Bravetti (PharmD, HEC Paris) is a strategic executive with a particular interest in scientific innovation and entrepreneurial adventures. He joined Brenus Pharma in 2020 and became Chief Executive Officer in 2022 with a clear mission, vision, and leadership to address current treatment limitations and make a significant impact for cancer patients. Thanks to his international experience in major pharmaceutical companies, he has successfully led the launches of therapeutics in immuno-oncology and biomolecular diagnostics across Europe and Asia. This experience has shaped his understanding of the biopharmaceutical industry and its unmet needs. Meet Paul Bravetti @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Like Lock and Key 🔐 Our resolve to unlocking the full potential of data and AI has never been more resolute. We’re thrilled to share that BioCopy AG, a trailblazer in AI-driven cancer drug discovery, has partnered with Genedata to supercharge their R&D efforts. By leveraging Genedata’s industry leading data model, BioCopy is poised to accelerate the journey of novel cancer treatments from the lab to the patients who need them most. "Genedata serves as our data backbone, ensuring seamless analysis across all projects and groups, which accelerates our cancer drug development process," said Joerg Birkenfeld, Ph.D., CSO of BioCopy. "Our automated engineering lab generates vast amounts of complex data, and Genedata structures this information into high-quality, contextualized insights that feed into our AI platform.” Discover how Genedata empowers leading biopharmaceutical and biotechnology firms to harness the power of AI: https://buff.ly/46aqupp #GenedataBiologics #GenedataDriven #cancerdrugs #AIdriven #StructuredData #Biotechnology #datascience #Innovation

🎯Originally emerging in the 1990s, #radioconjugates lost momentum due to #safety concerns and limited #efficacy. But today, thanks to advancements in technology and a better understanding of their potential, they’re experiencing a major resurgence. Radioconjugates are gaining attention for their ability to deliver highly targeted #radiation directly to #cancer cells, and the investment is flowing in—34 deals so far this year, with potential #milestones exceeding $4B USD. Some of the key players driving this investment include: 🔸 AstraZeneca & Fusion Pharmaceuticals 🔸 Novartis & Mariana Oncology 🔸 Aktis Oncology & Eli Lilly and Company There are currently 86 targets under investigation, with 33 yet to enter clinical trials. The most advanced? #PSMA, with 177Lu-PSMA-617 already securing #approval. But what’s exciting are the unique targets in the space, including: 🔹 Integrin: NUCLIDIUM AG 🔹 LRRC15: Radiopharm Theranostics & Lantheus 🔹 IL-2R Alpha: City of Hope Medical Center 🔹 PARP1: University of Pennsylvania & Trevarx Biomedical, Inc. Biomedical 🔹 Netrin-1: Centre Leon Berard & NETRIS Pharma & OranoMed 🔹 TEM1: Fusion Pharmaceuticals & AstraZeneca 🔹 Nectin-4: University of Saskatchewan 🔹 HSG: OncoOne Research & Development GmbH Radioconjugates are clearly gaining momentum, below is a summary of the top targets and their phase of development: #Biotech #Radioconjugates #Oncology #PrecisionMedicine #oncology #innovation #isotopes For more info, feel free to reach out.